(POXEL) Poxel - Ratings and Ratios

Poxel S.A. (PA:POXEL) is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for metabolic disorders, including type 2 diabetes and liver diseases. The companys lead product, TWYMEEG (Imeglimin), is an orally administered drug designed to address mitochondrial dysfunction. It has received regulatory approval in Japan for the treatment of type 2 diabetes. Poxels pipeline also includes PXL770, an adenosine monophosphate-activated protein kinase (AMPK) activator currently in Phase 2a clinical trials for chronic metabolic diseases, with a focus on liver-related conditions such as non-alcoholic steatohepatitis (NASH). Another key program is PXL065, which is in Phase 2 development for NASH and other chronic and rare metabolic disorders. The company has established strategic partnerships, including a licensing agreement with Enyo Pharma S.A.S. for a farnesoid X receptor (FXR) agonist in Phase 2a studies targeting hepatitis B and NASH, and collaborations with DeuteRx LLC for PXL065 and Sumitomo Pharma for the development and commercialization of Imeglimin. Founded in 2009, Poxel is headquartered in Lyon, France.

The companys approach focuses on targeting mitochondrial dysfunction and metabolic pathways, leveraging its expertise in small-molecule drug development. Poxels pipeline reflects a strategic emphasis on addressing unmet medical needs in metabolic and liver diseases, with a focus on both common and rare conditions. Its partnerships underscore a commitment to accelerating innovation and expanding its therapeutic offerings.

For more information, visit their website: https://www.poxelpharma.com